Peer-reviewed veterinary case report
Survival factors in dogs with pituitary hypercortisolism on trilostane
By Fracassi, F et al.·Published in The Veterinary record·2015·Department of Veterinary Medical Sciences, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
- Species:
- dog
Plain-English summary
A group of 85 dogs diagnosed with pituitary-dependent hypercortisolism (PDH), a condition that causes excessive cortisol production, were treated with a medication called trilostane. The average survival time for these dogs was about 852 days, with many living over a year or more. However, older dogs and those with high phosphate levels in their blood tended to have shorter survival times. While other factors like liver enzymes and blood pressure didn't seem to affect how long the dogs lived, high phosphate levels were identified as a concerning sign. Overall, trilostane helped many dogs manage their condition, but monitoring phosphate levels is important for predicting their health outcomes.
People also search for: dog pituitary-dependent hypercortisolism treatment · trilostane for dogs · dog high phosphate levels prognosis
Abstract
Pituitary-dependent hypercortisolism (PDH) is one of the most frequent endocrinopathies in dogs, but prognostic factors are largely unknown. The aim of this retrospective case series study was to determine the prognostic value of different clinical and clinicopathological variables evaluated in dogs newly diagnosed with PDH that were subsequently treated with trilostane. Medical records from one referral centre were evaluated. Eighty-five dogs with PDH were included. The median survival time was 852 days (range 2-3210 days); 60/85 (70 per cent) and 25/85 (29 per cent) dogs survived more than one and three years, respectively. In multivariable model analysis the length of survival of older dogs (HR 1.24, 95% CI 1.09 to 1.40) and dogs with higher serum phosphate concentrations (HR 1.35, 95% CI 1.01 to 1.81) was shorter. Serum phosphate concentrations were above the reference range in 37/85 (44 per cent) of animals. Clinical signs, liver enzymes, serum cortisol concentrations of the endocrine tests, proteinuria, systolic hypertension, the presence of concomitant disorders, and the frequency of trilostane administration were not associated with survival time. Hyperphosphataemia is a common finding in dogs with newly diagnosed PDH and represents a negative prognostic factor.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25170036/